Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How about sacarine is bad for your health? Years later, oops, it is better for you than sugar.
If you are right, then we should give Bush credit for the engineered collapse of the world economy as we maneuver our way to the lead. As the fingers of capitalism inner twine with the rest of the world and proceeds to drive captive societies free. I will personally take this theory..."What goes up, must come down, which must go up again". But, what do I know. My dad thinks the end is in 2012. We shall see!
You know it still might run, I dont know, very few stocks up last couple of days. I sold half for a loss at .10 this morning. Holding the rest for the gamble.
I bought some $4.00 Apr calls for .15c today. Worth a shot if we get a boost soon.
I cant find nada, on message boards, with a company call, nothing. Gonna hold and see. If I read something I will post asap.
same here left message and havent received a call back.
Profit.eom
Updated link, thought it looked like an institution was selling shares on Friday, looks like Bridgewater was liquidating. Once the institutions start buying like Vanguard we will see some positive price action. IMHO Have to have a golden stomach these days.
Mutual Funds buying, notice Vanguarg in particular
http://www.mffais.com/etfc.html
With the upside of it running to 2.50 or 3 by the time Tarp is announced.
Bond Insurors Mentioned
http://online.wsj.com/article/SB122593207136003391.html#printMode
READ ABK INFO
Today and A/h might have been the mother of all head fakes. Hope some bought the sub 2's
Wisconsin Approves Ambac's Request For Intercompany Facility
Nov 5, 2008 23:14:22 (ET)
DOW JONES NEWSWIRES
Ambac Financial Group Inc. (ABK) received approval Thursday from Wisconsin's insurance watchdog to transfer funds from the company's insurance arm to its financial-services unit after Moody's Investor Service cut Ambac's credit ratings.
"The Wisconsin Office of the Commissioner of Insurance reviewed and approved a request by Ambac Assurance to provide an intercompany facility to support Ambac's financial products," it said in a statement.
Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http://www.djnewsplus.com/al?rnd=MsA7vVf... You can use this link on the day this article is published and the following day.
(END) Dow Jones Newswires
November 05, 2008 23:07 ET (04:07 GMT)
No I have a margin account and all is good. I have to use the 3 day to trade in and out of my roth.
Lots of good long term and short term stock opportunities out there. I have told countless people I know to get an Etrade account and manage their own IRA if nothing else. I am starting to believe day after day that holding anything longer than the run is crazy. Big board or not. Some of my educated customers say that most of the stocks will slow considerably in the short term based on normal habits of stocks in these time periods. I havent had time to research, but if it is true, then Layton may have been ahead of the curve here. Lets see what we have, but I honestly feel, unless we touch 7700 on the dow, that this is easy money to at least 3.50 short term and 8-10 if Layton is telling us the truth. My problem is PATIENCE, lots of other opportunities out there. Just for the record I am a business owner, land lord, father, husband, and now.....Pattern Day Trader according to Etrade. LOL Holding the E until the cows come home! I will add when she shows signs of life.
PS I feel for you Arnie. I have lost plenty trying to figure all of this mess out, but you'll make it back 10 fold. Wamu was a $15,000 hit and I didnt jump out of any windows.
zzzzzzzzzzz Wake me up when the stock moves.eom
I hope you are right.
Just read on Yahoo that the checks are bouncing. I will find out Monday as I still have interest in this company.
Yep, how far will she go is the question.
Why has this stock not moved? Any ideas would be appreciated.
Spoke with IR this morning, they said Oct 24th PR of revenue projections for 2009 does NOT include Via deal. Will be rolling into X-mas next year and riding an upward trending market to boot. GL
Thanks for the insight. Absolutely some of the finest folks in the market reside in that room. Hats off!
WEll I bought more at 1.44 The captain stays on the ship
Citadel must be dumping their shares for capital. Only thing I can figure out, cc and quarterly wre positive moving forward.
Out of hand.eom
Agree, never had a problem with them.eom
svnt info...
Some in the room bought this one Monday, seems to be a conflict between what the analyst downgraded and the PR sent out by the company. Watch for a correction pr in the morning, I have emailed IR and will post when I get a response.
Savient Shares Tumble on Safety Data from Extension
By Anette Breindl
Science Editor
Shares of Savient Pharmaceuticals Inc. tumbled 73.5 percent Monday after the company presented data on its pegloticase (Puricase) for treatment-resistant gout. Even though the drug has met its endpoint in two Phase III studies, analysts were skeptical about a key safety issue, its prospects for approval, and the size of its market if it is approved.
Gout is a form of arthritis caused by an accumulation of uric acid in the joints that can result from making too much urea, or not metabolizing it properly. More than 1 million Americans have a gout attack each year, most of them males older than 40.
In data unveiled at the American College of Rheumatology, researchers presented data on two Phase III studies, GOUT1 and GOUT2. Topline results of both studies were first presented late last year. In both studies, the drug hit its endpoint, normalizing plasma uric acid levels during month 3 and month 6 of the trials. (See BioWorld Today, Dec. 14, 2007.)
New data presented at ACR showed that gout flares - acute gout attacks - decreased by about 40 percent in patients receiving pegloticase every two weeks compared to those receiving placebo. Gout tophi - deposits of crystallized uric acid in soft tissue - showed a complete response in patients receiving pegloticase every two weeks, as well as in the pooled response from patients receiving the drug every two weeks and every four weeks. But the third time was the charm for Puricase. The data included an uncontrolled open-label extension study known as GOUT 3 that failed to convince analysts of the drug's prospects.
The company's take on the data was positive: In a press release, Savient described the results as showing that "a substantial subset of patients who completed the Phase III clinical trials and enrolled in the [open-label extension] continued to show improvements in the resolution of their signs and symptoms of treatment-failure gout with continuing pegloticase treatment, extending the positive clinical results seen in Phase III. The two clinical efficacy endpoints of most interest, gout flares and gout tophi, showed an increasing proportion of patients with favorable response over time."
The East Brunswick, N.J.-based company said that the drug has "an acceptable safety and tolerability profile" when administered every two or every four weeks, and that "the emerging safety profile of long-term pegloticase therapy is consistent with that observed in the six double-blind studies, with no apparent new safety concerns related to long-term exposure."
On this point, however, some analysts disagreed.
Rachel McMinn of Cowen & Co. wrote in a note that "The surprising new information for investors is that Puricase in Phase III was associated with cardiovascular adverse events in 5 percent of patients vs. 0 percent for placebo patients."
Savient itself reported one cardiovascular death in the placebo group, but that patient died before receiving any placebo. Both Cowen, which downgraded Savient on Monday, and Jeffries & Co., which lowered its price target on the company, cited the higher rate of cardiac adverse events in the treatment group as cause for concern.
Analysts also said it is unlikely that pegloticase will win FDA approval on its first attempt, given that the company said it plans to file a biologics licensing application by the end of this month and expects approval in the first half of 2009. But Cowen's report cited a "lack of conviction" that pegloticase will receive first-pass FDA approval as one reason for the downgrade. Cowen noted that cardiovascular events as well as adverse infusion reactions, including anaphylactic shock-like reactions, "complicate the risk-reward profile of the drug."
And Jefferies and Co. noted that trouble could await from "an overly cautious FDA," particularly its division of anesthesia, analgesia and rheumatology, which was burned by the Vioxx episode.
Credit Suisse analysts, however, were more positive, saying that because of the small size of the study, 4:1 randomization, and patient comorbidities, it is impossible to ascertain any statistically significant imbalance.
One dual-edged sword for the company is that its drug is aimed at treatment-refractory patients who have exhausted other treatment options and are, on the average, very ill. While that makes side effects more acceptable than with a milder disease, it also means that the potential market is fairly small - another reason cited by analysts for their skepticism. Savient will present further data on the immune response of patients receiving long-term treatment with pegloticase at the conference tomorrow, and will conduct a conference call on Wednesday.
Shares of Savient (NASDAQ:SVNT) dropped $8.51, to close at $3.07.
Savient wasn't the only company presenting gout data at the ACR. San Diego-based Ardea Biosciences presented Phase I data at the meeting showing that its RDEA594, for hyperuricemia and gout, showed what the company termed "a favorable pharmacokinetic profile with low systemic clearance, favorable absorption and a half-life supporting once-daily dosing." 100 mg daily of the drug also significantly increased the excretion of uric acid.
And Xoma, Inc., of Berkeley, Calif., presented data showing that its XOMA052 blocks inflammation in a mouse model of gout.
The following data were presented at the American College of Rheumatology Annual Scientific Meeting in San Francisco.
• Amgen Inc.,
Yep, grabbed some 1.78 thought would be safe. Not sure anymore, time to have a garage sale and free some cash for more stocks. Once in a lifetime buying oppprtunities out there with no down end in sight. Getting ugly. Again
Wishing you well, I will pick up a few today also.
This topic came up on the paltalk after hours, thought I would post it here.
http://www.mondaq.com/article.asp?articleid=68224
We need an Amway type sales approach where we get our friends buying the products and so on and so on. Tell them they can invest in the stock. Be bigger than Msoft in 5 years. LOL Amway is good for penny stocks, thats it.
Just a random theory. Seems a terrible time to announce pr's considering the market conditions, but leads me to believe the company is rewarding long shareholders. Great times ahead here. Not sure how long, but I will buy along the way.
I do love it when a plan comes together. Anyone remember this bit of info.....http://www.reuters.com/article/pressRelease/idUS169788+30-Jun-2008+MW20080630
Started to buy more today ended up buying several others and marked em long term. Like Christmas for the 10 year investor. If market bottoms, guaranteed the E will be one of the last to creep up. But, creep up it will.
LOL All good.eom
Hey gang, I sold some E today at 2.40, had to leave for the afternoon and came back to a complete meltdown. The E held up quite well, waiting for sub 2 still. Not sure it will make it if it didn't today, even for a dip.
Yeah good for us. lol
Did some AXL DD tonight I know some in the room are in it...
Earning release date 10/31/08
Estimates range from +04/-.369/-.89
54 million shares outstanding with a current 116m market cap
10,000 employees Dividend as of 9/3/08 .08
This stock could get fun. GL all.
"I love it when a plan comes together"
The analyst missed the estimates not Etrade.
LOL Suzy, best post yet. Yeah none of us wre sweating it. I think the analyst missed their mark. They were figuring in the sale of the assets at their .24 mark and Layton gave them .09. I think we are a solid $3-4 stock, but I am not a buyer unless it goes below $2.00. I dont think so though. Layton is executing a plan and is ahead of the other boys.